Equities

Medx Health Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MDX:CVE

Medx Health Corp

Actions
  • Price (CAD)0.055
  • Today's Change-0.005 / -8.33%
  • Shares traded109.00k
  • 1 Year change-29.03%
  • Beta1.9667
Data delayed at least 15 minutes, as of Feb 11 2026 16:13 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.

  • Revenue in CAD (TTM)522.91k
  • Net income in CAD-5.30m
  • Incorporated1999
  • Employees--
  • Location
    Medx Health Corp1495 Bonhill Road, Unit # 1 MississaugaMISSISSAUGA L5T 1M2CanadaCAN
  • Phone+1 (905) 670-4428
  • Fax+1 (905) 670-4749
  • Websitehttps://medxhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kovo+Holdings Inc14.68m-8.63m4.43m--------0.3018-0.0538-0.05380.0919-0.05780.8026--33.43---47.17-----------58.77-----0.7981.60--5.45---25.26------
NuGen Medical Devices Inc589.43k-2.12m6.82m12.00------11.58-0.0092-0.00920.0026-0.03810.04610.783919.59---16.58---20.05--54.97---359.36--3.90--1.90--204.73--44.18------
VVT Med Inc9.50k-3.17m16.73m10.00------1,761.07-0.105-0.1050.0005-0.01170.0072-------241.79437.87----71.43---33,401.511,850.650.6354-19.392.530.00----15.43------
Medx Health Corp522.91k-5.30m18.07m--------34.55-0.0187-0.01870.0018-0.03320.49080.865113.37---497.63-619.54----33.6045.55-1,013.97-858.590.0567-1.70----7.37-10.6620.25------
Nanalysis Scientific Corp41.74m-12.38m21.46m130.00--1.58--0.5141-0.1092-0.10920.36720.0980.96336.855.00---28.57-21.20-44.19-30.0426.9635.26-29.66-37.300.6242-2.410.6248--59.8240.3215.95---9.96--
VentriPoint Diagnostics Ltd175.62k-4.06m22.36m--------127.35-0.0248-0.02480.0011-0.02780.3207--1.04---741.44-109.11---191.330.0086.67-2,311.87-8,206.33---8.35----93.513.27-0.9776------
Aurora Spine Corp24.50m-1.82m23.59m13.00--4.58--0.9631-0.0234-0.02340.31450.06661.521.935.51---11.30-13.83-17.27-19.1959.7452.84-7.44-10.241.10-5.450.4836--20.959.5140.34--17.34--
Data as of Feb 11 2026. Currency figures normalised to Medx Health Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.